Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that can block BCR-signaling. However, ibruti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, J, Chen, L, Cui, B, Wu, Christina, Choi, M Y, Chen, Y, Zhang, L, Rassenti, L Z, Widhopf II, G F, Kipps, T J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462858/
https://www.ncbi.nlm.nih.gov/pubmed/27904138
http://dx.doi.org/10.1038/leu.2016.368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462858/
https://www.ncbi.nlm.nih.gov/pubmed/27904138
http://dx.doi.org/10.1038/leu.2016.368

Ejemplares similares